Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. (28th November 2020)

• Record Type: Journal Article
• Authors: Spivey, Justin; Wrenn, Rebekah; Liu, Beiyu; Maziarz, Eileen; Kram, Bridgette
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 46:Number 2(2021)
• Page Start: 528
• Page End: 531
• Publication Date: 2020-11-28
• Subjects: enteral administration -- invasive fungal infection -- isavuconazole -- therapeutic drug monitoring; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13317
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: Invasive fungal infections often occur in patients with comorbidities that complicate oral administration. Serum concentrations of isavuconazole were characterized after enteral tube administration. Case description: Thirteen of 14 isavuconazole concentrations were >1 mg/dl (median 1.6 mg/dl) among those receiving enteral tube administration, which was comparable to intravenous (median 1.9 mg/dl). Higher concentrations were observed during oral administration (median 3 mg/dl). What is new and conclusion: Administration of isavuconazole via tube resulted in concentrations comparable to FDA‐approved routes of administration. This route may be feasible and appropriate for select patients. Abstract : Retrospective case series that characterized isavuconazole serum concentrations after enteral tube administration of opened capsule contents in 10 patients. Isavuconazole concentrations after enteral tube administration (median 1.6 mg/dL) were similar to concentrations obtained after the intravenous route (1.9 mg/dL) but lower than oral administration (median 3 mg/dL). Administration of isavuconazole via an enteral feeding tube resulted in concentrations comparable to FDA routes of administration and may represent an appropriate option for select patients.